Irinotecan Liposome（/m2）
Small molecule
Irinotecan Liposome（/m2） is one of 34 small molecule programs targeting Pancreatic Cancer. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Gemzar
GGynecologic Oncology Group
Preclinical
Byetta
AstraZenecaPreclinical
ABI-007
Bristol-Myers SquibbPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Active Comparator
ModernaPreclinical
Chemotherapy Agents
TakedaPreclinical
Meglitinides
SanofiPreclinical
Secretin-Ferring
FerringPreclinical
Concurrent Lenvatinib
TTrans Tasman Radiation Oncology Group
Preclinical
Rybelsus
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Irinotecan Liposome（/m2）. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- HHarbin Medical University